CSHL team develops mouse models of leukemia that predict response to chemotherapy

April 01, 2009

p53 gene network is key determinant of response; its attenuation causes drug resistance

Cold Spring Harbor, N.Y. - Being able to accurately predict how a given cancer will respond to chemotherapy would spare patients with non-responsive tumors the burden of undergoing toxic and ultimately unhelpful treatment. Just as important, knowing which of a patient's cancer-causing genetic lesions are contributing to drug resistance might help doctors redesign therapy for maximum benefit.

Researchers led by Professor Scott Lowe, Ph.D., of Cold Spring Harbor Laboratory (CSHL), have come closer to achieving these critical goals for human cancer therapy by developing new mouse models for human acute myeloid leukemia (AML), an aggressive and devastating cancer of white blood cells.

As Lowe and colleagues report in the April 1st issue of the journal Genes and Development, their models, which include treatment protocols that closely mimic current AML therapy in people, precisely recapitulate genetic associations that have been linked to favorable or adverse treatment responses in patients. These findings provide compelling evidence for the notion that such models can predict how human cancers will respond to therapy and help to identify genes promoting resistance or sensitivity to any cancer drug. The mouse models, the CSHL team notes, also serve as an effective test system for new drugs and treatment strategies in AML.

Need for a reliable prediction model

"By giving us a better understanding of how a cancer's genetic makeup, or 'genotype,' influences the outcomes of treatment, these models might help improve how existing drugs are used in people, and spur the design of more effective therapies," Lowe observes. "The new models are an important preclinical tool that will allow knowledge gained from cancer genetics to be put to effective use in the clinic."

The Lowe team's mouse models also provide valuable insights into how leukemia develops and progresses. Their study traces the intracellular network controlled by the p53 gene, a linchpin of the cell's anti-tumor defense response, as the key determinant of AML's aggressiveness and response to therapy.

Most patients with AML receive the same standardized treatment - an initial phase of intense chemotherapy followed by additional chemotherapy cycles or bone marrow transplantation. Yet only a quarter of patients are cured and most die within a few months. This diversity in treatment response is due to AML's genetic heterogeneity, meaning that the hundred or so mutations associated with this form of cancer occur in different combinations in each patient and influence therapeutic outcomes in different ways.

Some gene mutations in cancer have been correlated with clinical outcome. But AML has proved to be genetically too complex, and the current experimental systems for predicting treatment response too unreliable for the information to be used in a standard way in the clinic.

These standard systems, in which anticancer drugs were tested in human cancer-cell lines, do not factor in the effects of a real tumor's environment on its growth. At the same time, placing these cells into animals to create a so-called "xenotransplant" model has not been an effective solution, according to Johannes Zuber, M.D., a Clinical Fellow in the Lowe lab who played a key role in the research and is first author on the team's paper. The reason, explains Zuber, is that "the cells are so poorly defined at the genetic level and tend to defy analysis of the molecular factors that influence drug response."

Making mice with human-like AML

Lowe's group surmounted these problems by first identifying the most commonly occurring mutations in a group of 111 children with AML and then engineering these mutations into mice, which soon developed leukemia. Among the participating AML patients, the two most common mutations were observed to occur when chromosomes broke apart and reattached in new places. This incorrect fusion is thought to create cancer-causing genes, or "oncogenes," that encode so-called fusion proteins. It's the proteins that are the most immediate "cause" of cancer. They profoundly disturb the developmental program of cells.

Both oncogenic mutations identified by Lowe's team in AML patients have been well studied. The oncogene AML1/ETO previously has been associated with a favorable therapeutic outcome in people, while fusion oncogenes involving the MLL gene have been associated with an adverse outcome. To design an animal model that predicts these outcomes, the team introduced each mutation individually into stem and progenitor cells along with another oncogene, called Nras, which also appears frequently in human AML and is commonly found in concert with AML1/ETO and MLL fusion genes.

These altered stem cells were transplanted into mice that were first treated with radiation to destroy existing bone marrow cells. The altered stem cells then took over the "host" bone marrow and promoted the development of leukemia. To track leukemia onset and response to therapy, the scientists tagged all leukemia cells with a gene from fireflies that encodes an enzyme called luciferase, which makes leukemia cells glow and detectable by a ultrasensitive camera. Within weeks, the mice developed leukemias that showed the same genetic and pathological features as human AML.

"We were therefore certain," says Lowe, "that these animals were good models for studying the impact of cancer's genetic heterogeneity on therapy response and getting a correct read-out in terms of outcome prediction."

Sensitivity vs. resistance to chemotherapy

Experiments in which the team treated the mice with the same chemotherapy regimen administered to AML patients have proved Lowe to be correct. Just as in humans, leukemias in mice that received the AML1/ETO oncogene were also sensitive to chemotherapy and soon regressed, whereas MLL-triggered leukemias remained resistant and eventually killed their hosts.

The models also proved useful in helping the scientists identify the molecular basis of this difference in outcome. The chemosensitive mice with AML1/ETO-triggered leukemia had a distinct gene expression "signature" that was absent in the others; the genes whose expression was most significantly altered in the sensitive mice belong to a network controlled by p53 - the gene that masterminds the cell's anti-tumor defense.

Unlike the treatment-resistant mice, the treatment-sensitive mice showed a robust activation of the p53 network. This activation was critical for a favorable outcome: when the team knocked out p53 in the chemosensitive mice, their leukemia became drug-resistant and aggressive.

"These results in the new animal models suggest that AML patients diagnosed with the MLL chromosome rearrangement will not show durable responses to standard chemotherapy," according to Lowe, Zuber, and colleagues. "These patients should be offered alternative therapeutic approaches at diagnosis."

Cold Spring Harbor Laboratory

---

---

	The Chemotherapy Survival Guide: Everything You Need to Know to Get Through Treatment by Judith McKay (Author), Tammy Schacher RN OCN MSN (Author) When you're facing cancer treatment, it's easy to feel overwhelmed and alone. Between the hospital or clinic environment and the medical terminology used by doctors and health care professionals, you may feel as though you've entered a foreign country.Written by two experienced oncology nurses, this compassionate and comprehensive guide explains in plain English everything you need to know about your treatment, including what you can expect at each stage of chemotherapy and what you can do to prevent or minimize side effects. Packed with practical suggestions, nutritional advice, relaxation skills, and other techniques to help strengthen your body and calm your mind, The Chemotherapy Survival Guide is a must-have resource for anyone navigating this difficult...
	Handbook of Cancer Chemotherapy (Lippincott Williams & Wilkins Handbook Series) by Roland T. Skeel (Author), Samir Khleif (Author) Skeel's Handbook of Cancer Chemotherapy combines in one place the most current rationale and specific details necessary to safely administer chemotherapy for most adult cancers. The handbook is a practical, diseased-focused pocket reference that emphasizes the best current medical practice as it relates to the delivery of chemotherapeutic drugs. By focusing on specific plans for treatment, the book is an invaluable resource for the daily care of cancer patients.
	Chemotherapy and Radiation For Dummies by Alan P. Lyss (Author), Humberto Fagundes (Author), Patricia Corrigan (Author) An informative, compassionate guide for cancer patients and their loved onesEach year, more than 1 million people get treated for cancer, and most of these will undergo chemotherapy, radiation therapy, or both. This reassuring, optimistic guide helps people get a handle on treatment options and explains in plain English how chemotherapy and radiation therapy really work. It offers detailed advice on how to alleviate and cope with side effects-which range from hair loss to nausea to anemia-and describes how good nutrition, meditation, support groups, and other techniques and resources can help in the recovery process.
	83 Ways of Mitigating Chemotherapy Side Effects It was May 2002, when my father complained of an uneasiness in his stomach, he was experiencing slight pain in generally the lower abdomen. My father was a healthy person otherwise, with no major complaints apart from aches in the leg which we normally attributed to his walking long distances, as that was his hobby and he was very environment conscious in the times when people were not talking about environment or it had not become a fad to talk about. We gave him the usual home therapy for uneasiness, but the complaint persisted hence we took him to our family physician who was also like a family member. She immediately suspected something fishy and asked us to get a sonography done. The result was shocking for our family. My father was suffering from a unique syndrome atleast...
	Nurse's Chemotherapy Quick Pocket Reference by Debra S. Prescher-Hughes (Author) Nurse's Chemotherapy Quick Pocket Reference is a portable, quick-reference guide that provides quick access to the essentials of chemotherapy dosing administration and is arranged alphabetically by cancer type. This resource covers drug information for over 40 cancer types including bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, leukemia, lung cancer, ovarian cancer, prostate cancer, thyroid cancer, and more, and includes pre-treatment information, chair time, and major side effects for each drug entry. All the chemotherapy drug information you need in the palm of your hand!
	Questioning Chemotherapy: A Critique of the Use of Toxic Drugs in the Treatment of Cancer by Ralph W. Moss (Author) A revealing critique of chemotherapy, this book looks objectively at chemo's successes and failures.
	Chemo: Secrets to Thriving: From someone who's been there. by Roxanne Brown (Author), Barbara Mastej (Contributor), John S. Link M.D. (Contributor) The thought of chemotherapy can be overwhelming, but getting through it doesn’t have to be. Chemo: Secrets to Thriving helps lighten the load. In chronological order, step-by- step, you learn what might occur, why it happens, what you can do (with your doc’s approval), and who to contact for help. Chemo: Secrets to Thriving will be your friend, companion, and guide, giving you the resources to handle possible side effects and better manage your life during chemotherapy. Once you know the secrets in this book you may find yourself still able to enjoy life—and even thrive—while going through chemotherapy. Our endorsements aren’t from the usual celebrities, but from our celebrities: medical teams, fellow chemo travelers, and the people and places that support them.
	Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, Cancer Chemotherapy and Biotherapy) by Bruce A. Chabner (Editor), Dan L. Longo (Editor) Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes...
	The Cancer-Fighting Kitchen: Nourishing, Big-Flavor Recipes for Cancer Treatment and Recovery by Rebecca Katz (Author), Mat Edelson (Author) A Culinary Pharmacy in Your Pantry The Cancer-Fighting Kitchen features 150 science-based, nutrient-rich recipes that are easy to prepare and designed to give patients a much-needed boost by stimulating appetite and addressing treatment side effects including fatigue, nausea, dehydration, mouth and throat soreness, tastebud changes, and weight loss. A step-by-step guide helps patients nutritionally prepare for all phases of treatment, and a full nutritional analysis accompanies each recipe. This remarkable resource teaches patients and caregivers how to use readily available powerhouse ingredients to build a symptom- and cancer-fighting culinary toolkit. Blending fantastic taste and meticulous science, these recipes for soups, vegetable dishes, proteins, and sweet and savory snacks...
	Physicians' Cancer Chemotherapy Drug Manual 2012 (Jones & Bartlett Learning Oncology) by Edward Chu (Author), Vincent T. DeVita Jr. (Author) Completely Revised And Updated For 2012, The Physicians’ Cancer Chemotherapy Drug Manual Is An Up-To-Date Guide To The Latest Information On Standard Therapy And Recent Advances In The Field. Written By World-Class Experts In Clinical Cancer Therapeutics, This Essential Reference Provides A Complete, Easy-To-Use Catalog Of Over 100 Drugs And Commonly Used Drug Regimens—Both On- And Off-Label—For The Treatment Of All The Major Cancers. Special Features: Revised To Reflect Rapid Advances In The Field, Incorporating Treatment Strategies And New Drugs Like Abiraterone Acetate, Eributin, Ipilimumab, Romidepsin, Sipuleucel-T, And Vandetanib. A Specific Chapter Focused On Profiling Antiemetic Drug And Antiemetic Treatment Regimens. Diagrams Of Drug Structures And Pathways For Many Of The...